PTN
Palatin Technologies·AMEX
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 2
Bearish signal 0
Stock Price Surged Significantly
EPS Beats Expectation
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About PTN
Palatin Technologies, Inc.
A professional biopharmaceutical company
103 Carnegie Center Drive, Suite 300, Princeton, New Jersey 08852
--
Palatin Technologies, Inc., was incorporated under the laws of the State of Delaware on November 21, 1986. The company is a professional biopharmaceutical company developing first-in-class drugs based on molecules that regulate the activity of the melanocortin and natriuretic peptide receptor systems. The company's product candidates are targeted, receptor-specific treatments for diseases with significant unmet medical needs and commercial potential.
Company Financials
EPS
PTN has released its 2026 Q1 earnings. EPS was reported at 4.26, versus the expected 0, beating expectations. The chart below visualizes how PTN has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
PTN has released its 2026 Q1 earnings report, with revenue of 8.85M, reflecting a YoY change of NaN%, and net profit of 4.68M, showing a YoY change of 159.79%. The Sankey diagram below clearly presents PTN's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
